Dr. John Mott has been appointed vice president of Bioprocess Development, Cytovance Biologics. Dr. Mott has more than 30 years of experience with bacterial protein expression and more than 15 years of experience with CHO-based protein expression and production.

Prior to joining the company, he served in research and leadership positions at Pharmacia and Pfizer, and most recently, as vice president of lab services at Aragen Biosciences. He has led numerous industry alliances to explore and develop cellular biology technological advancements.

“Cytovance has created a new position within R&D Services responsible for overseeing clinical-stage client projects,” said Dr. Jesse McCool, senior vice president of R&D Services, “R&D has developed two distinct service groups to support Cytovance as we grow and build our commercial manufacturing business. We need to drive innovation and continuous improvements across all R&D operations while maintaining phase-appropriate technical approaches for each client’s program. John’s experience and contributions will be instrumental in fulfilling this strategy.”